Clinical Trial Update: BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) [Phase 3]

View source ↗

Summary

Phase 3 trial of laquinimod in relapsing-remitting multiple sclerosis completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)
• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2022-04-21